Skip to content
10-Q

Quarterly Report

AbbVie Inc. ABBV

0001551152-26-000017

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 1.77B sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.77B sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.77B sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $1.49B
Stock Repurchased Q1 2026 · Mar 31, 2025 $961M
Dividends Paid Q1 2026 · Mar 31, 2026 $3.09B
Dividends Paid Q1 2026 · Mar 31, 2025 $2.93B
Capex Q1 2026 · Mar 31, 2026 $265M
Capex Q1 2026 · Mar 31, 2025 $235M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $3.83B
Operating Cash Flow Q1 2026 · Mar 31, 2025 $1.64B
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Short Term Debt Q1 2026 · Dec 31, 2025 $2.5B
Cash And Equivalents Q1 2026 · Mar 31, 2026 $9.39B
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.23B
Stockholders Equity Q1 2026 · Mar 31, 2026 −$6.66B
Stockholders Equity Q1 2026 · Dec 31, 2025 −$3.27B
Current Liabilities Q1 2026 · Mar 31, 2026 $42.1B
Current Liabilities Q1 2026 · Dec 31, 2025 $43.29B
Current Assets Q1 2026 · Mar 31, 2026 $33.53B
Current Assets Q1 2026 · Dec 31, 2025 $29.06B
Total Assets Q1 2026 · Mar 31, 2026 $136.46B
Total Assets Q1 2026 · Dec 31, 2025 $133.96B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.39
Eps Diluted Q1 2026 · Mar 31, 2025 $0.72
Eps Basic Q1 2026 · Mar 31, 2026 $0.39
Eps Basic Q1 2026 · Mar 31, 2025 $0.72
Sga Expense Q1 2026 · Mar 31, 2026 $3.58B
Sga Expense Q1 2026 · Mar 31, 2025 $3.29B
Net Income Q1 2026 · Mar 31, 2026 $695M
Net Income Q1 2026 · Mar 31, 2025 $1.29B
Operating Income Q1 2026 · Mar 31, 2026 $3.99B
Operating Income Q1 2026 · Mar 31, 2025 $3.73B
Cost Of Revenue Q1 2026 · Mar 31, 2026 $4.22B
Cost Of Revenue Q1 2026 · Mar 31, 2025 $4B